Martin Geyer
Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.
Wiegand N, Geyer M, Lollo G, Wuillemin W, Aepli P, Frei R, Godat S, Manz M, Seewald S, The F, Wiest R, Borovicka J, Brand S, Buyse S, Degen L, Ehmann T, Riniker F, Riva D, Semela D, Truninger K, Utzinger E, Vonlaufen A. Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology. Praxis (Bern 1994) 2023; 112:635-641.
01.12.2023Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.
01.12.2023Praxis (Bern 1994) 2023; 112:635-641
Wiegand Nico, Geyer Martin, Lollo Gianluca, Wuillemin W A, Aepli Patrick, Frei Remus, Godat Sébastien, Manz Michael, Seewald Stefan, The Frans Olivier, Wiest Reiner, Borovicka Jan, Brand Stephan, Buyse Sophie, Degen Lukas, Ehmann Tobias, Riniker Florian, Riva Daniele, Semela David, Truninger Kaspar, Utzinger Ellen, Vonlaufen Alain
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
22.12.2010Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
22.12.2010Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory bowel diseases 2009
10.12.2009Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
10.12.2009Inflammatory bowel diseases 2009
Schoepfer Alain M, Straumann Alex, Seibold Frank, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Vavricka Stephan R, Michetti Pierre
Serum immunoglobin G4 (IgG4): an important marker in autoimmune pancreatitis?
Sulz M, Geyer M, Peter S, Degen L. Serum immunoglobin G4 (IgG4): an important marker in autoimmune pancreatitis?. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2006; 136:544-7.
19.08.2006Serum immunoglobin G4 (IgG4): an important marker in autoimmune pancreatitis?
19.08.2006Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2006; 136:544-7
Sulz Michael, Geyer Martin, Peter Shajan, Degen Lukas